• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer

    2/4/25 8:00:00 AM ET
    $AXTA
    $PLSE
    $TFX
    Paints/Coatings
    Consumer Discretionary
    Medical/Dental Instruments
    Health Care
    Get the next $AXTA alert in real time by email

    Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform

    Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the appointment of Jon Skinner as Chief Financial Officer, effective February 3, 2025.

    "I am excited to announce Jon as our next CFO, further building upon our momentum at Pulse Biosciences. His experience as a financial leader at both growth stage and scaled public diversified medtech companies will be extremely valuable in our efforts to advance our nanosecond PFA technology platform," said Paul LaViolette, Pulse Biosciences Co-Chairman and CEO. "Jon will be a fantastic addition to our leadership team and we look forward to benefitting from his strategic and financial insights as we scale commercialization and our operations."

    Jon Skinner is an accomplished financial leader with experience across the healthcare sector. He most recently served as Vice President, FP&A and Investor Relations at Copeland, a private equity backed industrial company. Prior to this role, Mr. Skinner was Vice President, Finance and Corporate Development at Imperative Care, a venture backed medical technology company. There, he spearheaded M&A, strategy, partnerships, and sales operations along with providing financial and strategic support for all development stage business units. While at Imperative Care, he also served as the interim CFO of Kandu Health during its spin-out and fundraising process. Prior to his time at Imperative Care, Mr. Skinner served as Vice President, Finance – Interventional Urology at Teleflex (NYSE:TFX), a global medical technology company. There he led accounting, FP&A, customer service, and sales operations for the Interventional Urology Business Unit, following his role as Senior Director, Corporate Development, where he helped close 25 M&A transactions. Prior to Teleflex, Mr. Skinner spent time at Axalta Coating Systems (NYSE:AXTA) working on its carve-out and IPO and at Duff & Phelps (now Kroll) in the Valuation Advisory Group. Mr. Skinner holds a Bachelor of Science and a Master of Business Administration from The Ohio State University.

    "I am thrilled to be joining Pulse Biosciences at this exciting point in the Company's history. I believe nanosecond PFA will be a disruptive catalyst to advance the treatment of several disease states representing very large markets," said Jon Skinner, Pulse Biosciences Chief Financial Officer. "I look forward to working alongside this talented and experienced management team and leveraging my experience to drive disciplined growth and operational excellence."

    Inducement Grants

    In connection with his appointment, the Company granted Mr. Skinner options to purchase 300,000 shares of the Company's common stock, in aggregate, at an exercise price equal to $20.93 per share, the closing price of the Company's common stock on January 31, 2024, the last trading day preceding Mr. Skinner's employment start date. These awards were approved by Pulse's Board of Directors and granted under its 2017 Inducement Equity Incentive Plan, as amended to date, as an inducement material to Mr. Skinner entering into employment with Pulse, in accordance with Nasdaq Listing Rule 5635(c)(4). Subject to Mr. Skinner being continuously employed by the Company through each applicable vesting date, half of the option shares will vest over four years, with 37,500 shares subject to the options vesting on the first four anniversaries of Mr. Skinner's employment start date, and half of the options shares will vest upon the achievement of product revenue and market capitalization milestones for the Company ranging from $2 billion to $5 billion. The Company is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

    About Pulse Biosciences®

    Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company's proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in Miami, Florida and maintains its office in Hayward, California.

    Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250204014968/en/

    Investors:

    Pulse Biosciences, Inc.

    Paul LaViolette, Co-Chairman and CEO

    [email protected]

    Or

    Gilmartin Group

    Philip Trip Taylor

    415.937.5406

    [email protected]

    Get the next $AXTA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $AXTA
    $PLSE
    $TFX

    CompanyDatePrice TargetRatingAnalyst
    Axalta Coating Systems Ltd.
    $AXTA
    5/8/2025$32.00Overweight → Neutral
    Analyst
    Axalta Coating Systems Ltd.
    $AXTA
    4/10/2025$38.00Neutral → Outperform
    Exane BNP Paribas
    Axalta Coating Systems Ltd.
    $AXTA
    4/7/2025$40.00Neutral → Buy
    UBS
    Teleflex Incorporated
    $TFX
    3/4/2025$235.00 → $140.00Neutral → Underperform
    BofA Securities
    Teleflex Incorporated
    $TFX
    2/28/2025$220.00 → $155.00Outperform → Sector Perform
    RBC Capital Mkts
    Teleflex Incorporated
    $TFX
    2/28/2025Outperform → Mkt Perform
    Raymond James
    Teleflex Incorporated
    $TFX
    2/28/2025$255.00 → $140.00Overweight → Neutral
    Piper Sandler
    Teleflex Incorporated
    $TFX
    2/27/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    More analyst ratings

    $AXTA
    $PLSE
    $TFX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Duggan Robert W bought $949,298 worth of shares (55,256 units at $17.18), increasing direct ownership by 0.13% to 42,328,717 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 8:02:46 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $777,771 worth of shares (45,404 units at $17.13), increasing direct ownership by 0.11% to 42,273,461 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/17/24 6:05:11 AM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duggan Robert W bought $972,344 worth of shares (56,054 units at $17.35), increasing direct ownership by 0.13% to 42,228,057 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      12/13/24 7:30:48 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $AXTA
    $PLSE
    $TFX
    SEC Filings

    See more
    • SEC Form 11-K filed by Teleflex Incorporated

      11-K - TELEFLEX INC (0000096943) (Filer)

      6/27/25 2:33:24 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Pulse Biosciences Inc

      144 - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

      6/13/25 4:14:15 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Pulse Biosciences Inc

      144 - PULSE BIOSCIENCES, INC. (0001625101) (Subject)

      6/12/25 4:25:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $AXTA
    $PLSE
    $TFX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Axalta Coating Systems downgraded by Analyst with a new price target

      Analyst downgraded Axalta Coating Systems from Overweight to Neutral and set a new price target of $32.00

      5/8/25 8:26:10 AM ET
      $AXTA
      Paints/Coatings
      Consumer Discretionary
    • Axalta Coating Systems upgraded by Exane BNP Paribas with a new price target

      Exane BNP Paribas upgraded Axalta Coating Systems from Neutral to Outperform and set a new price target of $38.00

      4/10/25 8:27:36 AM ET
      $AXTA
      Paints/Coatings
      Consumer Discretionary
    • Axalta Coating Systems upgraded by UBS with a new price target

      UBS upgraded Axalta Coating Systems from Neutral to Buy and set a new price target of $40.00

      4/7/25 8:35:47 AM ET
      $AXTA
      Paints/Coatings
      Consumer Discretionary

    $AXTA
    $PLSE
    $TFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Technology Officer Uecker Darrin sold $485,700 worth of shares (30,000 units at $16.19), decreasing direct ownership by 20% to 122,872 units (SEC Form 4)

      4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

      6/16/25 8:23:49 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care
    • Director Duncan Candace H was granted 1,051 shares, increasing direct ownership by 22% to 5,907 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:30 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Director Patil Neena M was granted 1,051 shares, increasing direct ownership by 67% to 2,626 units (SEC Form 4)

      4 - TELEFLEX INC (0000096943) (Issuer)

      5/13/25 5:03:06 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $AXTA
    $PLSE
    $TFX
    Leadership Updates

    Live Leadership Updates

    See more
    • DoorDash, TKO Group Holdings, Williams-Sonoma and Expand Energy Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, March 7, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 100, S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, March 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 100 are more representative of the mega-cap market space. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P

      3/7/25 6:19:00 PM ET
      $ALK
      $AMBC
      $ATI
      $BBWI
      Air Freight/Delivery Services
      Consumer Discretionary
      Property-Casualty Insurers
      Finance
    • Cagent Vascular Appoints Paul Wilson as Chief Commercial Officer to Drive Growth and Market Expansion

      Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the appointment of Paul Wilson as Chief Commercial Officer (CCO). In this role, Mr. Wilson will lead the company's commercial strategy, overseeing sales, marketing, clinical programming, and business development initiatives. His leadership will help expand awareness, accelerate growth, and strengthen market positioning of Cagent Vascular's proprietary serration balloon technology. Mr. Wilson brings many years of experience in the medical device industry, having held senior commercial leadership positions at Teleflex (NYSE:TFX) and Abbott (NYSE:ABT). With

      3/4/25 11:38:00 AM ET
      $ABT
      $TFX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Teleflex Announces Planned Retirement of Thomas Powell As Chief Financial Officer

      WAYNE, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that Thomas E. Powell, Teleflex's Chief Financial Officer, has decided to retire as Executive Vice President and Chief Financial Officer, effective April 1, 2025. John R. Deren, who currently serves as Corporate Vice President and Chief Accounting Officer of Teleflex, will succeed Mr. Powell as Executive Vice President and Chief Financial Officer, effective April 2, 2025. Following his retirement, Mr. Powell will serve as a consultant to the company through March 31, 2026 to support continuity and a smooth transition. "Tom has announced his des

      2/27/25 6:36:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $AXTA
    $PLSE
    $TFX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

      WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication. On Febr

      7/1/25 6:30:13 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

      WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guinea, Colombia, Egypt and Turkey. Key highlights include: The pre-specified CVC subgroup analysis evaluated the impact of Chlorhexidine-impregnated CVCs on CLABSI rates using CLABSI rates per 1,000 CL (central-line)-days.70.5% reduction in the incidence of CLABSI in patien

      6/12/25 6:29:59 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Highlights Prostate Health and Quality-of-Life Awareness Through Two Key Public Initiatives During Men's Health Month

      Timed with National Men's Health Month, the Prostate Monster ad campaign shines a light on quality-of-life issues associated with benign prostatic hyperplasia or BPH—a condition affecting millions of men1—and encourages them to take control of their health. The Teleflex Prostate Education Express, a mobile training and education center, is on a national tour to educate physicians and the community on prostate health quality-of-life issues associated with BPH and the importance of organ spacing to protect against potential rectal side effects in advance of prostate cancer radiation treatment.   WAYNE, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading globa

      6/11/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care

    $AXTA
    $PLSE
    $TFX
    Financials

    Live finance-specific insights

    See more
    • Teleflex Completes Acquisition of BIOTRONIK's Vascular Intervention Business

      WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex's portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establish Teleflex's global footprint in the fast-growing peripheral intervention market, and provide a channel for Teleflex products that currently have a peripheral indication. On Febr

      7/1/25 6:30:13 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Teleflex Announces Quarterly Dividend

      WAYNE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 16, 2025, to shareholders of record at the close of business on May 20, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgi

      5/12/25 6:30:00 AM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results

      Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources for the launch of the nsPFA Percutaneous Electrode expected in the second half of 2025. The Company expects to commence a U.S. clinical trial in mid-2025 to expand evidence for the nsPFA Percutaneous Electrode System as a treatment for benign thyroid nodules. Surgical AF Ablation Received EU approval to expand the clinical protocol for the nsPF

      5/8/25 4:05:00 PM ET
      $PLSE
      Medical/Dental Instruments
      Health Care

    $AXTA
    $PLSE
    $TFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Teleflex Incorporated

      SC 13G/A - TELEFLEX INC (0000096943) (Subject)

      11/14/24 1:28:29 PM ET
      $TFX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Axalta Coating Systems Ltd.

      SC 13G - Axalta Coating Systems Ltd. (0001616862) (Subject)

      11/13/24 2:12:25 PM ET
      $AXTA
      Paints/Coatings
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Axalta Coating Systems Ltd.

      SC 13G/A - Axalta Coating Systems Ltd. (0001616862) (Subject)

      11/12/24 9:50:12 AM ET
      $AXTA
      Paints/Coatings
      Consumer Discretionary